Wednesday, October 14, 2020

October 14: Johns Hopkins COVID 19 Report




COVID-19


Updates on the COVID-19 pandemic from the Johns Hopkins Center for Health Security.

Additional resources are available on our website.

Subscribe to our newsletter

The Johns Hopkins Center for Health Security also produces US Travel Industry and Retail Supply Chain Updates that provide a summary of major issues and events impacting the US travel industry and retail supply chain. You can access them here.

Tomorrow - Upcoming Center Event: COVID-19 and the US Criminal Justice System- Evidence for Public Health Measures to Reduce Risk

Join the Johns Hopkins Center for Health Security and the Center for Public Health and Human Rights at the Bloomberg School of Public Health as they release a new report detailing COVID-19’s impact on the United States’ criminal justice system. You are invited to join us on Thursday, October 15 (2-3 PM EDT), for the release of the report and a discussion on the findings and recommendations.

COVID-19 outbreaks are growing fast in carceral facilities (eg, jail, prisons, detention centers). As of June 6, the COVID-19 incidence rate in prisons was 5.5 times higher than that of the overall US population, and the age-adjusted mortality rate was 3 times higher. Register for the webinar.

EPI UPDATE The WHO COVID-19 Dashboard reports 38.00 million cases and 1.08 million deaths as of 10:00am EDT on October 14.

UNITED STATES

The US CDC reported 7.87 million total cases and 214,446 deaths. The US daily COVID-19 incidence continues to climb, now up to 50,181 new cases per day, the first time above 50,000 daily cases since August 17. At this pace, the US should surpass 8 million cumulative cases in the next 4-5 days. The US COVID-19 mortality continues to hold steady at approximately 675-700 deaths per day. It has been approximately 4 weeks since the US COVID-19 incidence began its current surge. COVID-19 mortality has not yet shown indication of an increase at the national level, but as discussed below, some states are reporting expected increases in COVID-19 mortality, following several weeks of increasing incidence.

More than half of all US states have reported more than 100,000 cases, including California with more than 800,000 cases; Texas and Florida with more than 700,000; New York with more than 400,000; Georgia and Illinois with more than 300,000; and Arizona, New Jersey, North Carolina, and Tennessee with more than 200,000. We expect Texas to surpass 800,000 cumulative cases in the next several days.

While the national average daily mortality has not yet started to increase, state-level mortality in some parts of the country are beginning to exhibit expected surges, following several weeks of increased incidence. Many state COVID-19 websites or dashboards do not display incidence and mortality data in a way that facilitates this analysis; however, some independent efforts do, such as the STAT News COVID-19 Tracker. While a number of states are beginning to exhibit increasing COVID-19 mortality, several notable examples stand out.

Wisconsin’s summer resurgence began in mid-June, and its current surge started in early September. The corresponding increases in mortality started around mid-July and late September, respectively—both lagging the incidence trend by approximately 3 weeks. Wisconsin’s COVID-19 mortality has doubled since the end of September. In Utah, the current surge began in mid-September, with incidence tripling since that time. Approximately 2 weeks later, the mortality began to surge as well, increasing by 400% since then. Missouri’s COVID-19 incidence began increasing in mid-June, peaked in mid-August followed by a slight decrease, and then surged again starting in early September. Missouri’s mortality has followed a similar trend, doubling from mid-July to early September and then doubling again from mid-September to now. North and South Dakota are both exhibiting substantial spikes in mortality. North Dakota’s current surge in incidence began around mid-August, which was followed by a surge in mortality starting in early September. North Dakota’s COVID-19 incidence has tripled since the start of the surge, and its mortality has increased by more than 400%. South Dakota’s surge began in mid-August as well, and the increase in mortality followed approximately 3-4 weeks later. South Dakota’s COVID-19 incidence and mortality have both increased nearly 500% over that time.

Notably, North and South Dakota and Utah have relatively small populations, so the total number of daily deaths remains low (ie, fewer than 15 per day). On a per capita basis, however, South Dakota’s daily mortality (0.65 daily deaths per 100k population) is more than double the national average (0.25 deaths/100k), and North Dakota’s (1.44 deaths/100k) is nearly 6 times the national average. The mortality in both states is still increasing rapidly. Utah went from 0.03 daily deaths per 100k population—12% of the current national average—to 0.15 deaths per 100k—up to 60% of the current national average—in less than 3 weeks.

A number of other states have exhibited similar trends with respect to incidence and mortality, but not necessarily to the same degree as these examples.

The Johns Hopkins CSSE dashboard reported 7.88 million US cases and 216,278 deaths as of 1:30pm EDT on October 14.

ARIZONA SOCIAL DISTANCING & MASK ORDERS A study conducted by state health officials in Arizona (US) and the US CDC COVID-19 Response Team evaluated the effects of social distancing measures implemented in Arizona. The study, published in the CDC’s MMWR, found that COVID-19 incidence began to stabilize and then decrease approximately 2 weeks after the implementation of a series of social distancing measures that aimed to mitigate community transmission risk. The researchers evaluated trends in the 7-day average of Arizona’s daily COVID-19 incidence from January 22-August 7, compared against the dates that various social distancing measures were implemented at the state and local levels.

From June 1 to June 15, approximately 2-4 weeks after the state’s “stay at home” order ended, Arizona’s average daily incidence increased by more than 150%, which prompted state and local governments to take action. On June 17 the state government permitted local jurisdictions to mandate mask use, and a number of county, city, and tribal governments did so over the following week, covering approximately 85% of the state’s population. Additionally, state officials strengthened social distancing restrictions, including limiting the size of large gatherings, closing or limiting operations at “businesses where mask use and social distancing were difficult to maintain” (eg, restaurants, bars, and gyms/fitness centers), and encouraging mask use in areas where local mandates were not in place. In late June/early July, approximately 2 weeks after local mask mandates began to take effect, Arizona’s COVID-19 peaked and then began to decline. Arizona’s daily incidence decreased 75% from its peak, following the sustained use of local and statewide COVID-19 community mitigation measures. While this study is not able to determine a causal relationship between the measures and decreased transmission, the relative timing of the implementation and the decrease in incidence provide further evidence that social and physical distancing and mask use could be key tools in mitigating SARS-CoV-2 transmission risk.

NEW YORK CITY In an effort to contain emerging COVID-19 hotspots, New York City implemented neighborhood-specific control measures. The restrictions are implemented based on hotspot zones, designated as Red, Orange, or Yellow based on the incidence rate (as well as areas not currently designated as hotspots), and the restrictions include limitations on the operation of schools; businesses, including restaurants and bars; places of worship; and large gatherings. During the first weekend of the newly imposed social distancing and mask requirements, New York City issued 62 summons and more than $150,000 in fines to individuals and organizations for violations of the new policies.

Notably, the affected areas predominantly affect Orthodox Jewish communities, which have been singled out by state and local officials, including New York Governor Andrew Cuomo and New York City Mayor Bill DeBlasio, for not adhering to social distancing policies, including large gatherings for Jewish holidays. Notably, 5 of the summons issued over the weekend were to places of worship. Some in the community and neighborhoods have protested the new restrictions, arguing that they are facing discrimination while the rest of the city continues to operate under much looser social distancing policies. The protests led to the arrest of one local activist on charges of inciting a riot as well as unlawful imprisonment of a journalist, following an alleged assault of journalist reporting on the protests. Local Catholic leaders have also opposed the new restrictions, which limit the capacity at all places of worship in the affected areas. While the effort aims to avoid blanket, city-wide restrictions by targeting higher-risk areas, it is unclear if the highly localized restrictions could be effective in reducing transmission and preventing spillover of the virus into other parts of the city.

HOSPITAL PREPAREDNESS A study published in Infection Control and Hospital Epidemiology examined the preparedness of US community hospitals, as opposed to large academic medical centers, during the US COVID-19 epidemic. The researchers surveyed 50 community hospitals across 6 states in the Southeast region in April and May to determine the availability of critical personal protective equipment (PPE), including face masks and shields, N95 respirators, and powered-air purifying respirators (PAPRs). The survey also asked about other COVID-19 practices, including patient and staff screening, universal mask use, and suspension of non-essential procedures.

Among the respondents, 48% of community hospitals reported an insufficient supply (ie, “almost out or none” or “few days supply”) of PAPRs, 30% with insufficient supply of N95 respirators, 26% with insufficient surgical masks, and 16% with insufficient face shields. Additionally, approximately 80% of these hospitals implemented strategies to extend their supply of PPE, including extending use of various PPE items—including face masks, respirators, and face shields—or disinfecting and reusing them. The survey provides further data that community hospitals have struggled to maintain adequate PPE supply during their response to COVID-19.

More than 75% of the hospitals reported implementing universal masking for staff, patients, and visitors, while only 8% mandated mask use for only healthcare providers. The vast majority (90%) implemented some form of daily screening for hospital staff. By the time the survey was conducted, some facilities had begun to resume some non-essential procedures, including elective surgeries, although the degree to which this occurred varied by facility. Finally, approximately 30% of hospitals utilized on-site laboratories for SARS-CoV-2 testing, and nearly 12% utilized local health department laboratories. The report indicates that at least 30% utilized major private laboratory networks (Quest and LabCorp), but it does not specify how the remaining hospitals managed testing demand.

EARLY TRANSMISSION DYNAMICS A study by the US CDC COVID-19 Response Team, published in the US CDC’s MMWR, examined SARS-CoV-2 transmission dynamics among different age groups in US hotspots during the US summer resurgence. This study builds on previous analysis of US hotspot areas. The study included 767 US counties that were identified as COVID-19 hotspots in June and July—defined as reporting more than 100 COVID-19 cases over a 7-day period and increasing incidence over the previous 3-7 days—which represented approximately 24% of all US counties and 63% of the entire US population.

The researchers found that test positivity among individuals aged 0-17 and 18-24 years began to increase approximately 1 month before the county qualified as a hotspot. Test positivity increased progressively in older age groups, following a surge among the younger population. On average, test positivity at the time a county was identified as a hotspot was highest among the 18-24 age group (14%), followed by the 0-17 age group (11%). The test positivity decreased with age among older age groups: 25-44 years (10%), 45-64 years (8%), and 65 years and older (6%). The South and the West regions reported higher test positivity across all age groups during this period, which corresponds to the regions that were most severely affected during the summer.

The findings support the idea that transmission among younger portions of the population precedes increased risk among older individuals. It is important to reduce transmission of SARS-CoV-2 in younger population groups in order to protect older, more vulnerable portions of the population.

HANDWASHING A study by the US CDC COVID-19 Response Team, published in the US CDC’s MMWR, aimed to understand how handwashing behavior in the US has changed since the start of the COVID-19 pandemic. The researchers compared survey data from October 2019, prior to the emergence of SARS-CoV-2, to a survey administered in June 2020 to evaluate how public perceptions and behaviors had changed with respect to handwashing. The survey data was collected from Porter Novelli Public Services’ fall and summer ConsumerStyles surveys. The fall survey included 3,624 respondents, and the summer survey included 4,053 respondents. Both surveys asked participants to select from 6 options (as many as applicable) in which they “would be likely to remember to wash their hands”: (1) after using the bathroom at home; (2) after using the bathroom in public; (3) after coughing, sneezing, or blowing one’s nose; (4) before eating at home; (5) before eating at a restaurant; or (6) before preparing food at home.

The researchers identified a statistically significant increase in the odds of participating in 4 of the 6 situations, all of them except before preparing food and after using the bathroom in public. Both of these scenarios had high participation in the fall 2019 survey, so there was not much room for improvement for those 2 options. It is important to note that the survey did not ask participants whether their individual behavior had changed—only the scenarios in which they would wash their hands—nor did it ask about COVID-19 in the context of handwashing behavior. These findings do, however, provide evidence that handwashing behaviors have changed since the start of the COVID-19 pandemic.

VACCINE CLINICAL TRIALS Johnson & Johnson (J&J) announced that it has paused the Phase 3 clinical trial for its candidate SARS-CoV-2 vaccine due to an unexplained illness in one of the participants. In a press release this week, J&J did not share detailed information about the adverse event. The company emphasized that the “study pause” is not uncommon in vaccine trials and that it differs from a “regulatory hold,” which would be mandated by a regulatory authority (eg, US FDA). It is still uncertain if the participant who experienced these events was part of the vaccinated group or the placebo group, and more information is expected to be released in the coming weeks.

This is the second leading SARS-CoV-2 vaccine candidate to pause a clinical trial in the US. AstraZeneca’s Phase 3 clinical trial has not yet restarted in the US after pausing in September, although trials have resumed in other countries. Additionally, Eli Lilly also suspended an ongoing trial for its monoclonal antibody cocktail this week due to safety concerns. The pauses in these trials reinforce the critical need to conduct large-scale clinical trials to evaluate efficacy and identify adverse events that may occur too infrequently to be captured in smaller study groups. The pauses and relative transparency from these pharmaceutical companies provides some measure of confidence that the trials are being conducted in an ethical manner and that safety remains a high priority.

HERD IMMUNITY Three professors published an open letter calling for an approach to containing the COVID-19 pandemic that they call “Focused Protection.” The document, titled The Great Barrington Declaration argues that existing social distancing and other community mitigation policies risk long-term public health impact, and the proposal aims to achieve herd immunity in the absence of vaccination. The authors call for those “at minimal risk of death to live their lives normally [while] protecting those who are at highest risk.” In support of this plan, they call for lower-risk individuals to return to normal social activity—including in-person school and extracurricular activities and normal operations at restaurants, bars, and other businesses—and essentially isolating higher-risk individuals.

A number of health experts have highlighted the problematic nature of this proposal. Notably, UN Secretary-General Dr. Tedros Adhanom Ghebreyesus described a herd immunity approach in the absence of a vaccine “unethical.” Beyond the expected increase in COVID-19 hospitalizations and deaths that would accompany increased incidence among lower-risk populations, public health experts have highlighted a number of problems with the plan. Evidence continues to emerge about longer-term health effects from COVID-19, including among previously healthy individuals and those who do not experience severe acute illness. Increased incidence, even among lower-risk populations, could also risk patient surge that could threaten health systems, particularly as the Northern Hemisphere approaches influenza season. While documented cases of reinfection have been limited so far in the pandemic, it remains unclear how long immunity conferred by natural infection can last. Additionally, it is clear that transmission among certain populations (eg, correctional facilities, schools) can quickly spread to households and the community, so increasing transmission among lower-risk individuals is likely to increase transmission risk for higher-risk individuals.

SCHOOL SCREENING & TESTING The Johns Hopkins Center for Health Security collaborated with the Duke University Margolis Center for Health Policy, with support from The Rockefeller Foundation, to develop guidance for implementing SARS-CoV-2 testing protocols at schools. The report outlines a framework for screening and testing at schools to mitigate school-based transmission risk. The framework enables schools to tailor their testing protocols based on local risk assessments in order to ensure that testing strategies meet local needs. The framework addresses multiple types of tests, including diagnostic and antigen tests; multiple testing strategies, including individual and pooled testing; the likelihood and impact of false positive and negative test results; and other mitigation strategies that can affect transmission risk. In further support of this effort, The Rockefeller Foundation is collaborating with the US Department of Health and Human Services to distribute at least 12,000 rapid antigen tests to 5 pilot cities to evaluate the framework.

October 14: 2862 New COVID-19 Cases in Illinois

Boone is reporting 31 new cases of COVID-19. Illinois today reported 2,862 new cases, including 49 additional confirmed deaths.


No photo description available.

Tuesday, October 13, 2020

October 13: 2851 New COVID 19 Cases in Illinois

37 new COVID 19 cases in Boone County

Monday, October 12, 2020

Update on Foxconn and Wisconsin


Wisconsin just denied Apple's biggest supplier a huge tax break after the company failed to build a factory that promised to bring thousands of jobs to the state

Katie Canales

7 hours ago

<?XML:NAMESPACE PREFIX = "[default] http://www.w3.org/2000/svg" NS = "http://www.w3.org/2000/svg" />

foxconn apple wisconsin factory

A journalist photographs the site where President Donald Trump will speak later at the ground breaking for the Foxconn Technology Group on June 28, 2018 in Mt Pleasant, Wisconsin. Andy Manis/Getty Images

  • Wisconsin has rejected Foxconn's application for tax subsidies on the grounds that the electronics manufacturer has not built the factory that it had promised, The Verge reported Monday.
  • The company made a deal with the state in 2017 to build a facility that would produce large-screen TV displays and said it would create 13,000 jobs.
  • But the Wisconsin Economic Development Corporation rejected Foxconn's application for tax subsidies since it found that it had only hired 281 people by the end of 2019 who meet the qualifications listed in the contract.
  • Foxconn is Apple's biggest manufacturing partner, with a Chinese factory that produces well over half of the world's supply of iPhones.
  • Visit Business Insider's homepage for more stories.

Wisconsin has denied Foxconn, Apple's biggest supplier, a tax break after the electronics manufacturer failed to build a factory in the state, The Verge reported Monday.

The state made a deal with Foxconn in 2017 for a large LCD facility, dubbed a Gen 10.5 factory, to be built in the state that would create 13,000 jobs. In return, Foxconn would receive tax subsidies in increments, totaling around $4 billion.

But according to the Wisconsin Economic Development Corporation (WEDC), the company has yet to employ the number of people required for Foxconn to receive the subsidies, per the report. The agreement stipulated that Foxconn would need to have at least 520 people under employment by the end of 2019 to receive the tax subsidies. Foxconn claimed to have hired 550 people, but according to the WEDC, only 281 of them meet the qualifications listed in the contract.

"The Recipients are ineligible for tax credits because of their failure to carry out the Project," the WEDC wrote in its letter to Foxconn, according to The Verge. "The fact that the Recipients have neither built, nor started to build or operate, the required Generation 10.5 TFT-LCD Fabrication Facility (the "10.5 Fab") is not in dispute."

Foxconn did not immediately respond to Business Insider's request for comment.

The agreement between Foxconn and Wisconsin has hit snags since its inception, but its failure to build the 20-million-square-foot factory remains the biggest sore point of the deal. The factory was originally intended to produce advanced large-screen TV displays, but after the company found that route to be too expensive, it changed its plans to instead manufacture smaller screens.

The company attempted to tweak its existing contract with the state to align with its updated plans, which would include a smaller factory and a much lower number of people employed there, but a revised deal was never made.

President Donald Trump visited the factory site in 2018 as the administration was moving forward with its call to reenergize manufacturing on American soil.

Foxconn is the largest iPhone maker in the world. Its massive manufacturing facility in Zhengzhou, China — otherwise known as "iPhone City," as Business Insider reported in 2018 produces over half of the world's supply of the smartphones.

Above is from:  https://www.businessinsider.com/foxconn-apple-denied-tax-breaks-wisconsin-2020-10

October 12: 2742 New COVID 19 Cases in Illinios

Boone is reporting 85 new cases of COVID-19. Illinois today reported 2,742 new cases, including 13 additional confirmed deaths.

Boone’s case count represents cases reported into our electronic reporting system from 12:01 a.m. on Saturday, October 10th through today, October 12th at 12:01 a.m.



October 12: Johns Hopkins COVID 19 Report



COVID-19


Updates on the COVID-19 pandemic from the Johns Hopkins Center for Health Security.

Additional resources are available on our website.

Subscribe to our newsletter

The Johns Hopkins Center for Health Security also produces US Travel Industry and Retail Supply Chain Updates that provide a summary of major issues and events impacting the US travel industry and retail supply chain. You can access them here.

Upcoming Center Event: COVID-19 and the US Criminal Justice System- Evidence for Public Health Measures to Reduce Risk

Join the Johns Hopkins Center for Health Security and the Center for Public Health and Human Rights at the Bloomberg School of Public Health as they release a new report detailing COVID-19’s impact on the United States’ criminal justice system. You are invited to join us on Thursday, October 15 (2-3 PM EDT), for the release of the report and a discussion on the findings and recommendations.

COVID-19 outbreaks are growing fast in carceral facilities (eg, jail, prisons, detention centers). As of June 6, the COVID-19 incidence rate in prisons was 5.5 times higher than that of the overall US population, and the age-adjusted mortality rate was 3 times higher. Register for the webinar.

CORRECTION: In Friday’s COVID-19 Update, we mistakenly referred to former Vice President Joe Biden as “President Biden.” This was a typographical error.

EPI UPDATE The WHO COVID-19 Dashboard reports 37.42 million cases and 1.07 million deaths as of 9:30am EDT on October 12. The WHO reported a new record high for global weekly incidence for the fourth consecutive week. The global total reached more than 2.25 million cases—an increase of nearly 10% over the previous week. Additionally, the WHO reported 378,044 new cases on Saturday, a new daily record.

Total Daily Incidence (change in average incidence; change in rank, if applicable)

1. India: 70,960 new cases per day (-7,484)

2. USA: 49,243 (+5,986)

3. Brazil: 25,670 (-470)

4. France: 16,543 (+5,029; ↑ 1)

5. United Kingdom: 14,391 (+4,676; ↑ 2)

6. Argentina: 13,674 (+1,223; ↓ 2)

7. Russia: 11,960 (+2,879; ↑ 1)

8. Spain: 10,169* (+862; ↓ 2)

9. Colombia: 8,038 (+2,038; ↓ 1)

10. Mexico: 7,523 (+3,045; new)

Per Capita Daily Incidence (change in average incidence; change in rank, if applicable)

1. Andorra: 1,083 daily cases per million population (+577; ↑ 1)

2. Czech Republic: 462 (+224; ↑ 4)

3. Montenegro: 396 (-16)

4. Israel: 390 (-223; ↓ 3)

5. Belgium: 332 (+103; new)

6. Netherlands: 323 (+121; ↑ 3)

7. Argentina: 303 (+27; ↓ 2)

8. France: 253 (+77; new)

9. Iceland: 253 (+129; new)

10. Bahamas: 242 (+18; new)

*Spain’s average daily incidence is not reported for today; these values correspond to the previous day’s averages.

Israel fell out of the top 10 in terms of total daily incidence, and it was replaced by Mexico. Israel’s daily incidence has decreased by nearly 50% since its peak in early October. Andorra surpassed Israel for #1 globally in terms of per capita daily incidence. Andorra is reporting more than 1,000 daily cases per million population—the first country to do so— which is more than double its daily incidence from the previous week. Andorra has a population of approximately 77,000 people, so this translates to only 80-85 total cases per day; however, the extremely high per capita rate is very concerning. A number of European countries are climbing the list in terms of per capita daily incidence. Notably, Belgium, France, and Iceland all entered the top 10, and the Netherlands and Czech Republic jumped multiple places from last week. Spain fell out of the top 10, but its incidence increased compared to the previous week. Moldova and Bahrain also fell out of the top 10.

India’s daily incidence continues the decline from its peak in mid-September, but the country surpassed 7 million cumulative cases. If India continues on this trajectory, it will likely surpass the US for #1 globally in terms of cumulative cases in the coming days or weeks. Additionally, Brazil’s epidemic continues its decline since late July, but it surpassed 5 million cumulative cases.

UNITED STATES

The US CDC reported 7.70 million total cases and 213,614 deaths. The US daily COVID-19 incidence continues to climb, now up to 47,844 new cases per day, the highest since August 18. On Saturday, October 10 (corresponding to October 9 data), the CDC reported 58,302 new cases, the highest daily total since August 7. The US COVID-19 mortality appears to have leveled off at approximately 675-700 deaths per day over the past week or so. Considering that mortality tends to lag 2-3 weeks behind changes in COVID-19 incidence, we will monitor these trends closely for early signs of increasing mortality stemming from the current resurgence.

Half of all US states have reported more than 100,000 cases, including California with more than 800,000 cases; Texas and Florida with more than 700,000; New York with more than 400,000; Georgia and Illinois with more than 300,000; and Arizona, New Jersey, North Carolina, and Tennessee with more than 200,000.

The Johns Hopkins CSSE dashboard reported 7.78 million US cases and 214,917 deaths as of 1:30pm EDT on October 12.

PEER PRESSURE The age distribution for COVID-19 cases has shifted toward younger adults over the past several months, in the US and elsewhere. Researchers from the US CDC COVID-19 Response Team, in collaboration with state health officials in Wisconsin (US), sought to better characterize potential drivers of this phenomenon by evaluating characteristics of COVID-19 patients between the ages of 18 and 23 in Winnebago County, Wisconsin. The study, published in the US CDC’s MMWR, utilized information from Wisconsin’s Electronic Disease Surveillance System and interviews with young adults, community leaders, and owners of businesses frequented by young adults. The researchers identified exposure to misinformation, conflicting or inconsistent public health messaging, and low perceived severity of disease as factors that may contribute to riskier behavior among young adults.

The researchers also identified numerous barriers to consistent and effective mask use among this age group, including the absence of a local or national mask mandate, social or peer pressure to not wear a mask, and mixed perceptions regarding the effectiveness of mask use. The researchers identified work and social gatherings as principal sites for potential exposure among this age group. Notably, the study was conducted in March-July, prior to the start of the ongoing COVID-19 surge in Wisconsin and the start of classes for the 2020-21 school year, which could affect the volume and type of communication aimed at this age group, the types of exposure they face, and their perceptions of COVID-19 risk. The researchers recommended that future public health messaging be tailored to the young adult population, with a focus on empathy, personal and community responsibility, and peer or social pressure to not wear masks.

US PRESIDENT US President Donald Trump’s physician, Dr. Sean Conley, issued a statement on Saturday that indicates that President Trump is no longer considered to be infectious. Dr. Conley stated that President Trump is now more than 10 days since the onset of his symptoms and that he has been fever-free for at least 24 hours, which meets the standards outlined by the US CDC for ending the isolation period. Additionally, the statement reports that “advanced diagnostic tests” detected no “evidence of actively replicating virus.” Notably, traditional PRC-based diagnostic tests can detect viral RNA, including fragments of destroyed virus, in a recovered COVID-19 patient, even if s/he is not infectious. This is why the US CDC isolation guidance is based on the time since symptom onset rather than on obtaining negative diagnostic tests. The evidence that the virus is no longer replicating provides evidence that President Trump is recovering and is no longer a transmission risk. Having completed the isolation period, President Trump aims to resume his campaign schedule, including in-person rallies. And while the second presidential debate, originally scheduled for October 15, was cancelled, the final presidential debate currently remains on the schedule for October 22.

UNITED KINGDOM In response to an ongoing resurgence of COVID-19, the UK government unveiled a 3-tier “lockdown” system to help contain the epidemic in severely affected areas. UK Prime Minister Boris Johnson addressed Parliament earlier today to discuss the new system. The decision to implement a new set of social distancing measures comes at a time when UK health officials are facing a “tipping point” in the UK’s epidemic and as the country looks ahead to influenza season. According to media reports, the system will include Medium, High, and Very High risk categories, each with its own set of corresponding restrictions. In areas at very high risk—which will reportedly include Liverpool—any mixing between households or “bubbles” will be prohibited, and all pubs and bars will be closed. The government will also issue travel advisories for these areas in an effort to reduce travel into or out of severely affected areas. In high-risk areas, household mixing will be permitted outdoors but not indoors. Medium-risk areas will currently cover most of the UK, and the current restrictions will remain in place. Schools will reportedly remain open for all 3 tiers. Parliament is expected to vote on the new measures tomorrow, and they could be implemented starting Wednesday. Details are still emerging about the new system, and we will provide updates in Friday’s briefing.

Several industry groups representing UK hospitality businesses, including pubs and bars, are reportedly planning to challenge the new restrictions in court. The groups argue that the ongoing resurgence is largely driven by household outbreaks rather than transmission at hospitality-related businesses. Notably, previous research has identified the significant role of household transmission during the pandemic; however, the index patients for household outbreaks would likely need to be exposed in the community in order to bring the disease home. The UK government has reportedly committed to subsidizing wages for affected individuals; however, the financial support may not be enough for individuals or businesses.

OBESITY The US CDC updated its guidance regarding individuals at elevated risk of severe COVID-19 disease and death due to underlying medical conditions, including more detailed information regarding the risk associated with obesity. The previous iteration of the guidance noted that individuals with a body mass index (BMI) of 30 or higher were at elevated risk of severe COVID-19 disease. The most recent update includes multiple categories: obesity (BMI of greater than 30 but less than 40) and severe obesity (BMI of 40 or greater). Additionally, the guidance notes that individuals “having overweight” (BMI of greater than 25 but less than 30) may also be at elevated risk of severe disease. The expanded risk group could potentially mean that 72% of all Americans are at elevated risk of severe disease based solely on their weight. Notably, BMI does not accurately characterize body fat percentage or overweight/obesity in all individuals, but it provides a simplified metric to help categorize risk associated with these conditions.

Multiple recent studies provide data that help to better characterize COVID-19 risk stemming from overweight and obesity. A study published in the International Journal of Obesity found that individuals with overweight and obesity were at elevated risk of death and intubation (eg, for mechanical ventilation) compared to those with normal weight, even after adjusting for age, gender, and commonly associated conditions such as diabetes, asthma, and hypertension. Another study, published in Brain, Behavior and Immunity evaluated COVID-19 risk associated with various lifestyle factors, including “smoking, physical inactivity, obesity, and excessive alcohol intake” based on data from more than 380,000 individuals in the UK. The researchers found strong associations between COVID-19 hospitalization and smoking, physical inactivity, and obesity, but not excessive alcohol intake. Utilizing a combined “lifestyle score”—on a scale from 0 to 8, with 0 being optimal—that includes a variety of these factors, individuals with “less favourable” scores (5 or greater) were more than 4 times likely to be hospitalized compared to individuals with “optimal” scores. 

REMDESIVIR Researchers conducting the ACTT-1 clinical trial for remdesivir published the final report on their findings in The New England Journal of Medicine (NEJM). Preliminary findings from the study were announced in April, via a press release issued by Gilead Pharmaceuticals, the drug’s manufacturer, and a statement by the US National Institute for Allergy and Infectious Diseases. Preliminary analysis was also published in NEJM in September—the URL is the same for both articles, so you need to use an archived version to compare them. The preliminary analysis indicated that remdesivir decreased the time to recovery for COVID-19 patients who were hospitalized.

The final report arrives at a similar conclusion and provides additional data on the study population and outcomes. Based on data from 1,062 patients—541 who received remdesivir treatment and 521 placebo-controlled controls—treatment with the drug resulted in a statistically significant decrease in recovery time. The median recovery time for patients treated with remdesivir was 10 days, compared to 15 days for the control group—a decrease of 33%—and the treatment group was more likely to show clinical improvement by Day 15. Patients in the treatment group also exhibited improved mortality at Day 15 and Day 29; however, these results were not statistically significant. Additionally, the data suggest that the drug also helped mitigate the risk of progressing to more severe disease, based on a reduction in “serious adverse events” and lower incidence of “new oxygen use” in the treatment group, compared to the placebo group.

YOUNG CHILDREN Researchers from the Medical University of Warsaw (Poland) published findings from their analysis of an outbreak at a nursery. The study, published in the US CDC journal Emerging Infectious Diseases, found that very young children (ie, under the age of 3) who are asymptomatic may effectively transmit SARS-CoV-2 to adults and other children. Following notification that a staff member was exposed, the facility was closed and PCR-based diagnostic testing was conducted among children, staff, and family members of children and staff. Despite measures to mitigate transmission risk, including mask use and multiple independent cohorts of children and staff, the outbreak resulted in 29 confirmed infections. The infections represented 27% of the individuals tested, including 8 children at the nursery and 12 family members with no direct exposure at the nursery. This study illustrates both that transmission can occur among children and staff in school-type settings and at home and that transmission associated with school-based outbreaks can extend into the community.

CRISPR-BASED DIAGNOSTICS A new CRISPR-based diagnostic test could provide the ability to detect SARS-CoV-2 in as little as 5 minutes. Other CRISPR-based SARS-CoV-2 diagnostic tests have been developed previously, but this newest test does not require RNA amplification, saving time and resources and allowing the test to be conducted at the point of care. The new test was developed by a team led by Dr. Jennifer Doudna, who was recently awarded the Nobel Prize for her work in pioneering the use of CRISPR. The test is not as sensitive as conventional PCR-based tests; however, the researchers demonstrated (preprint) that it is capable of both detecting the presence of SARS-CoV-2 virus and quantifying the amount present in a specimen, another advantage over traditional diagnostic tests. If the CRISPR-based diagnostic test is successfully validated, the rapid, on-site results and the ability to quantify viral load could allow clinicians to better tailor treatments.

A detailed protocol for another CRISPR-based diagnostic was also recently published in The New England Journal of Medicine. This test, developed by researchers at the Massachusetts Institute of Technology’s (MIT’s) Broad Institute, demonstrated results in 15 to 45 minutes with 93% sensitivity and 98% specificity, when compared against the US CDC’s standard RT-qPCR diagnostic test. The researchers noted that the streamlined test was suitable for use in “low-complexity clinical laboratories” using “minimal equipment.” Expanded testing capacity, particularly for tests that do not require advanced laboratory capabilities, could be a critical tool for containing outbreaks, operating in low-resource settings, and screening larger populations.

SURVIVAL ON SURFACES While respiratory transmission is generally understood to be the primary driver of the COVID-19 pandemic, a study published in the journal Virology has raised new concerns for fomite transmission. Researchers from the Commonwealth Scientific and Industrial Research Organisation at the Australian Centre for Disease Preparedness analyzed the survival of SARS-CoV-2 virus on various surfaces under controlled laboratory conditions. They found wide variations in survival time based on surface type and temperature. Most notably, infectious virus survived on glass, stainless steel, and paper and polymer bank notes (ie, paper currency) for at least 28 days at 20°C (68°F). In contrast, viable virus was detected on cotton cloth after only 14 days. As temperature increased, the survival time of infectious virus decreased. At 40°C (104°F), infectious virus lasted less than 24 hours on cotton and less than 48 hours on all other surfaces.

The researchers inoculated the surfaces using a viral load and fluid matrix designed to mimic a typical COVID-19 patient. Humidity remained relatively standard at 40-50% during the tests, and the experiment was conducted in darkness to negate the effect of UV light, which can kill the virus. While the study illustrated that SARS-CoV-2 could potentially survive on surfaces for longer than previously thought, it is important to note that these standardized conditions do not necessarily represent real-world conditions. Additionally, the virus titer did reduce by 50% on all surfaces within 3 days and by 90% on all surfaces within 10 days, which illustrates that fomite transmission risk decreases over time, even without effective disinfection practices.

Sunday, October 11, 2020

New England Journal of Medicine says vote Trump out


Trump hails his COVID 'cure' as leading medical journal calls him 'dangerously incompetent' on pandemic


David Knowles

Editor



President Trump continued to hail an experimental monoclonal antibody treatment as a “cure” for COVID-19, telling conservative radio host Rush Limbaugh in a Friday interview that it sped his recovery from the disease and was “better than a vaccine.”

“I was not in great shape, but we have a medicine that healed me, that fixed me,” Trump said of the antibody “cocktail” manufactured by Regeneron Pharmaceuticals. “It’s a great medicine. I recovered immediately.”

Since being released on Monday from Walter Reed National Military Medical Center, where he was treated for three days after being admitted with a high fever, chills and breathing problems, Trump has often pointed to the antibody therapy he undertook at the hospital as a “cure” for COVID-19. There is no known cure for the disease caused by exposure to the coronavirus, and the FDA has not, so far, approved the drug’s use for treating COVID-19.

Just as he had done with the antimalarial drug hydroxychloroquine, which he took in May as a prophylactic against COVID-19, the president didn’t hesitate describing Regeneron’s “cocktail” in the most glowing possible terms.

- ADVERTISEMENT -

“We have a cure. More than just a therapeutic, have a cure,” Trump said of the antibody treatment, adding, “This is better than a vaccine.”

Both Regeneron and the drug manufacturer Eli Lilly have released limited studies showing that monoclonal antibody treatments can decrease the viral load of COVID-19 in patients who have not been hospitalized for the disease. Trump’s assertions about the drug have not been proved in any study, and he received other drugs, including remdesivir and the steroid dexamethasone, since testing positive for COVID-19 on Thursday, Oct. 1.

On Tuesday, Trump voiced his frustration with the Food and Drug Administration for requiring drug manufacturers to follow safety protocols that will slow the availability of a vaccine until after the Nov. 3 election.

Perhaps the central issue in the presidential election is Trump’s handling of the coronavirus pandemic, and during his rambling two-hour phone call with Limbaugh, the president again complained about not receiving enough praise for his administration’s efforts to slow the spread of the virus.

“We’ve done such a good job on the pandemic. We get zero credit,” Trump said.

US President Donald Trump gestures to the press as he arrives at the White House wearing a facemask upon his return from Walter Reed Medical Center, where he underwent treatment for Covid-19, in Washington, DC, on October 5, 2020. (Photo by NICHOLAS KAMM / AFP) (Photo by NICHOLAS KAMM/AFP via Getty Images)

President Trump arrives at the White House on his return from Walter Reed medical center on Monday. (Nicholas Kamm/AFP via Getty Images)

As of Friday afternoon, at least 7.6 million Americans had tested positive and at least 213,000 had died from COVID-19, far more than in any other country.

On Thursday, the New England Journal of Medicine broke precedent and for the first time in its history published an editorial calling for a president to be voted out of office. The editors disagreed that Trump did “such a good job on the pandemic.”

“We know that we could have done better. China, faced with the first outbreak, chose strict quarantine and isolation after an initial delay. These measures were severe but effective, essentially eliminating transmission at the point where the outbreak began and reducing the death rate to a reported 3 per million, as compared with more than 500 per million in the United States,” the editorial stated. “Countries that had far more exchange with China, such as Singapore and South Korea, began intensive testing early, along with aggressive contact tracing and appropriate isolation, and have had relatively small outbreaks. And New Zealand has used these same measures, together with its geographic advantages, to come close to eliminating the disease, something that has allowed that country to limit the time of closure and to largely reopen society to a prepandemic level. In general, not only have many democracies done better than the United States, but they have also outperformed us by orders of magnitude.”

While Trump again pledged Friday that his administration would rush the antibody drug to hospitals so that COVID-19 patients could receive it “free of charge,” he did not include specifics as to how the expensive treatment would be funded. Nor did he update the status of possible emergency use approval from the FDA for the drug, saying only that he had already “signed it.”

Founded in 1812, the New England Journal of Medicine is considered perhaps the world’s leading medical journal, publishing research on drugs, research and medical treatment. After reviewing the Trump administration’s handling of the pandemic, its editors concluded that the president’s leadership had been “dangerously incompetent.”

“When it comes to the response to the largest public health crisis of our time, our current political leaders have demonstrated that they are dangerously incompetent. We should not abet them and enable the deaths of thousands more Americans by allowing them to keep their jobs,” the editorial stated.